Tesla Says Continuing Investment In Nevada, Says Will Be Investing Over $3.6B More To Continue Growing Gigafactory Nevada, Adding 3K New Team Members, Two New Factories

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.